News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DiscoveryBioMed Awarded Phase 1 SBIR Catalyst Grant under The Recovery Act by the National Institutes of Health (NIH) to Discover Anti-Inflammatory Drugs



4/20/2010 1:43:14 PM

BIRMINGHAM, Ala.--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $200,000 Small Business Innovations Research (SBIR) Phase 1 grant by the National Institutes of Health (NIH) to continue research into the discovery and development of anti-inflammatory phytochemicals to address complications associated with nasal and pulmonary inflammation, dermatitis, and kidney disorders with an inflammatory component. DiscoveryBioMed, Inc. (DBM) will be working with ChromaDex Corp. (OTCBB: CDXC), who will be providing a library of natural products and phytochemicals to screen in their human cell platform.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES